Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

12775880 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-18

Study Completion Date

2023-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2013, the NHS started a vaccination program in some regions of England to provide free flu vaccines to children aged 2 years or older, and younger than 16 years. The program has since been rolled out across England. Most children are given a vaccine that is sprayed into their nose. In clinical trials, this vaccine has been shown to protect children from experiencing severe flu symptoms. It is important to describe how it is used, and what happens to children who receive it in the wider community. This evidence will help the NHS to check that the vaccine roll out runs as planned and produces the intended benefits.

This study aims to: (1) describe how many children each year receive flu vaccines, and describe the characteristics of children who are and aren't vaccinated for influenza; (2) test how often children receiving the vaccine see their GP or a hospital doctor for symptoms related to flu, compared to those who don't; and (3) to test what groups of children are more or less likely to receive a flu vaccine. To answer these objectives, the study will use the Clinical Practice Research Datalink, linked to Hospital Episode Statistics and the Office for National Statistics database.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nasal and Systemic Immune Responses to Nasal Influenza Vaccine

NCT04110366

Influenza Vaccine Virus Shedding

COMPLETED NA

Efficacy & Safety of Nasal Influenza Immunisation in Children

NCT02549365

Influenza Vaccines Efficacy and Safety

COMPLETED PHASE4

FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV

NCT04222595

Immunization

COMPLETED NA

Safety of Nasal Influenza Immunisation in Children With Asthma

NCT02866942

Asthma

COMPLETED PHASE4

Safety of Nasal Influenza Immunisation in Egg Allergic Children

NCT01859039

Egg Hypersensitivity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Live Attenuated Influenza Vaccination (LAIV) has been offered to children through a rolling national program in England since 2013. Previous observational studies identified trends in LAIV uptake that varied with demographic and clinical profiles.

The general aim of this study is to provide up-to-date epidemiological evidence on the uptake of the influenza vaccines, and influenza related HCRU outcomes in children in England. The specific study objectives are given below.

Primary objective:

1\. To evaluate the uptake of influenza vaccines in children aged ≥2 and \<18 years in England between 2012 and 2020 for LAIV, QIV, and influenza vaccinations where the product is not specified

Secondary objectives:

2.1 To describe usage patterns of LAIV in England between 2012 and 2020. 2.2 To describe HCRU associated with laboratory confirmed influenza and/or influenza-like-illness (ILI) in England between 2012 and 2020 and assess the relative impact of LAIV on HCRU use of LAIV vs no vaccination 2.3 To describe demographics and clinical characteristics of individuals vaccinated with LAIV or not vaccinated against flu by any vaccine in each flu season between 2012 and 2020 2.4 To estimate a DAG aligned model for LAIV uptake in England based on demographic and clinical factors for each flu season and across multiple seasons between 2012 and 2020

The study will include all research eligible aged between ≥2 and \<18 years in the study period, with 6 months of history in CPRD before their first influenza vaccination. It will use the Clinical Practice Research Datalink data (vaccinations, diagnoses, characteristics) linked to Hospital Episode Statistics (HCRU). Logistic regression analyses will be used to test for factors associated with vaccine uptake, and outcomes between vaccinated and unvaccinated children. The study will provide up-to-date epidemiological evidence on the uptake of LAIV and its impact on HCRU related to ILI in children in England. This may be used by the NHS for planning and evaluation of the childhood influenza vaccination program.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LAIV Vaccinated cohort

All individuals receiving LAIV between 2 and \<18 years within a given flu season between 2012 and 2020.

No interventions assigned to this group

Unvaccinated cohort

All individuals between 2 and \<18 years with no record of influenza vaccinations in a given flu season

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In each flu season, the following criteria apply:

* Aged ≥6 months and \<2 years on the 1st September
* Have a high-risk condition as listed in the Green Book.

Exclusion Criteria

* Were deceased or had migrated out of their practice prior to the 1st September in the current influenza season.
* Were recorded has receiving both QIV and LAIV in the current influenza season.

Minimum Eligible Age

0 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No